Camurus Ab
Clinical trials sponsored by Camurus Ab, explained in plain language.
Swedish pharmaceutical company developing long-acting drug delivery products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New shot every 2 weeks could control tumor growth in gut cancers
Disease control OngoingThis phase 3 trial compares a new form of octreotide (CAM2029) given as a shot every 2 weeks to standard monthly injections in 332 people with advanced neuroendocrine tumors of the gut or pancreas. The main goal is to see if the new drug delays tumor growth better than current tr…
Phase: PHASE3 • Sponsor: Camurus AB • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New shot could shrink enlarged livers and ease pain
Disease control OngoingThis study tests a drug called CAM2029 (octreotide) given as a weekly or every-other-week shot to people with symptomatic polycystic liver disease. The goal is to see if it can shrink the liver and reduce symptoms like belly pain, bloating, and nausea. About 71 adults with an enl…
Phase: PHASE2, PHASE3 • Sponsor: Camurus AB • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC